

## **Daftar Pustaka**

1. Kemenkes RI. Peraturan Menteri Kesehatan RI Nomor 413 Tahun 2020 Tentang Pedoman Pencegahan dan Pengendalian Covid-19 Revisi 5. 2020.
2. Satgas Covid-19. No Title [Internet]. Situasi Covid-19 di Indonesia tanggal 23 Juni 2021. 2021 [cited 2021 Jun 24]. Available from: <https://covid19.go.id/>
3. Statistik Kasus Covid-19 Jawa Tengah [Internet]. Statistik Kasus Covid-19 Jawa tengah. 2021 [cited 2021 Jun 24]. Available from: <https://corona.jatengprov.go.id/data>
4. Informasi Coronavirus (Covid-19) Semarang [Internet]. 2021 [cited 2021 Jun 24]. Available from: <https://siagacorona.semarangkota.go.id/halaman/covid19>
5. Dinas Kesehatan Propinsi Jateng. Nakes Konfirm dilaporkan pada evaluasi Covid Jawa Tengah Minggu ke-19 [Internet]. 2021. Available from: [www.admincoronajateng](http://www.admincoronajateng)
6. Kemenkes RI. Keputusan Direktur Jenderal Pencegahan Dan Pengendalian Penyakit Nomor Hk.02.02/4/ 1 /2021 Tentang Petunjuk Teknis Pelaksanaan Vaksinasi Dalam Rangka Penanggulangan Pandemi Corona Virus Disease 2019 (Covid-19).
7. WHO. The Sinovac COVID-19 vaccine: What you need to know [Internet]. 2 Juni 2021. 2021 [cited 2021 Jul 11]. Available from: <https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know>

8. WHO. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations [Internet]. 1 Jun 2021. 2021 [cited 2021 Jul 11]. Available from: <https://www.who.int/news-room/detail/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations>
9. Unggulkraiwit P. Covid-19 Vaccine [Internet]. 10 Mei 2021. 2021 [cited 2021 Jul 10]. Available from: <https://www.vejthani.com/2021/05/covid-19-vaccines/>
10. World Health Organization, Strategic Advisory Group of Experts on Immunization (SAGE), SAGE Working Group, on COVID-19 Vaccines. Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2. 2021;(May):1–7. Available from: [https://apps.who.int/iris/bitstream/handle/10665/338484/WHO-2019-nCoV-vaccines-SAGE\\_recommendation-BNT162b2-2021.1-eng.pdf?sequence=1&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/338484/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1-eng.pdf?sequence=1&isAllowed=y)
11. Akbar S. No Title [Internet]. Butuh Waktu Untuk Membentuk Antibodi Setelah Vaksinasi Covid-19. [cited 2021 Mar 1]. Available from: <https://probolinggokab.go.id/butuh-waktu-untuk-membentuk-antibodi-setelah-vaksinasi-covid-19/>
12. Gallaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020;580:576–7.
13. Ni L, Ye F, Li Cheng M, Feng Y, Qiang Deng Y, Zhao H et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19

- Convalescent Individuals. *Immunity* [Internet]. 2020;52(6):971-977.e3.  
Available from: <https://doi.org/10.1016/j.immuni.2020.04.023>
14. M. Altmann D JBR. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. *Sci Immunol* [Internet]. 2020;5(17 July 2020):2–7. Available from: <http://immunology.science.org/content/5/49/eabd6160>
15. Dan Li D HLQ. SARS-CoV-2: vaccines in the pandemic era. *Mil Med Res* [Internet]. 2021;8(1):1–15. Available from: <https://doi.org/10.1186/s40779-020-00296-y>
16. Fransisco A C V. What Do We Know Antibody responses to SAR CoV 2. Elsevier. 2021;Immunobiol.
17. Subowo. Imunologi Klinik. Jakarta: Sagung Seto; 2013.
18. Swamy, G.K, Putnam R. Maternal Immunization to Benefit The Mother, fetus and Infant. Elsevier. 2014;41(4):521–34.
19. Gombart A, Pierre A MS. A review of micronutrients and the immune system-working in harmony to reduce the risk of infection Nutrients. Google Sch. 2020;(12).
20. Delven P. immune disorders biology of the immune system effects of aging [Internet]. Oktober 2014. 2014 [cited 2021 Jul 11]. Available from: [http://www.merckmanuals.com/home/\\_system.htm](http://www.merckmanuals.com/home/_system.htm)
21. Clow A. The Physiology of Stress. In Jones F and Bright J Stress: Myth, Theory and Research. Jones Bartlett Pub. 2001;47–61.
22. Suwondo A. Pengaruh Terapi Spiritual Emotional Freedom Technique

- (SEFT) Terhadap Kadar Kortisol dan Immunoglobulin E. J Ilmu Keperawatan dan Kebidanan [Internet]. 2006; Available from: [www.ejournal.stikestelogorejo.ac.id](http://www.ejournal.stikestelogorejo.ac.id)
23. M. Dan J, Mateus J, Kato Y, M.Hastie K, Dawen Yu E, E.FFaliti C et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (80- ) [Internet]. 2021;371(6529). Available from: <http://http://science.sciencemag.org/>
24. Zimmermann P CN. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32(2):1–50.
25. Lumley S, O'Donnell D, E. Stoesser N, C. Matthews P, Howarth A, Hatch S et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med [Internet]. 2021;384:533–40. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa2034545>
26. KIm, J.H; Marks, F; Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021;27:205–11.
27. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. What level of neutralising antibody protects from COVID-19? medRxiv [Internet]. 2021;2021.03.09.21252641. Available from: [https://www.researchgate.net/publication/350008879\\_What\\_level\\_of\\_neutralising\\_antibody\\_protects\\_from\\_COVID-19](https://www.researchgate.net/publication/350008879_What_level_of_neutralising_antibody_protects_from_COVID-19)
28. Kara E., Tanir F., Demirhindi H., Mete B., Cetiner S. et al. Humoral immune response in inactivated SARS-CoV-2 vaccine: When should a booster dose be administered? MedRxiv [Internet]. 2021; Available from:

<https://www.medrxiv.org/content/10.1101/2021.07.08.21260194v1>

29. Lo Sasso B, Giglio RV, Vidali M, Scazzone C, Bivona G, Gambino CM, et al. Evaluation of Anti-SARS-CoV-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine. *Diagnostics* [Internet]. 2021;11(7):1135. Available from: <https://www.mdpi.com/2075-4418/11/7/1135>
30. Dirjen Pencegahan dan Pengendalian Penyakit. Surat Edaran Ditjen P2P Kemenkes RI nomor HK.02.01/I/2524/2021 tentang Vaksinasi Covid-19 Bagi Penyintas [Internet]. 2021. Available from: SE Vaksinasi bagi Penyintas.PDF - Covid-19.go.id
31. Padoan A, Bonfante F, Cosma, Di Chiara C, Sciacovelli L, Pagliari M et al. Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers. *Clin Chem Lab Med*. 2021;59(8).
32. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel F, Michael Rajah M et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature* [Internet]. 2021;596:pages 276–280. Available from: <https://doi.org/10.1038/s41586-021-03777-9>
33. Krer, C; Zehner, M; Ercanoglu, MS; Gieselman, L; Rohde, C; Halwe , S et all. Longitudinal isolation of potent near-germline SARS-CoV-2 neutralizing antibodies from COVID-19 patients. *Cell*. 2021;182:834–54.
34. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S et al. Neutralizing antibody responses to SARS-CoV-2 in COVID-19 recovered Patient Cohort and Their Implications. *medRxiv* [Internet]. 2020;(April 2020). Available from: <https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v2>

35. Marzuki I, Bachtiar E, Zuhriyatun F, Mahardika A, urba V, Kurniasih H D. Covid-19 Seribu Saru Wajah [Internet]. Jakarta: Yayasan Kita Menulis; 2021. Available from: <https://scholar.google.com/scholar?oi=bibs&cluster=12587253061019296043&btnI=1&hl=en>
36. Carrillo J, Izquierdo N, Avila C, Pradenas E, Clotet B BJ. Humoral immune responses and neutralizing antibodies against SARS-CoV-2: implication in pathogenesis and protective immunity. Elsevier [Internet]. 2021;538(7 November 2020):187–91. Available from: [www.elsevier.com/locate/ybbrc](http://www.elsevier.com/locate/ybbrc)
37. Jara A, Undurraga E, Gonzalez C, Peredes F, Fontacella T, Jara G et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. *N Engl J Med* [Internet]. 2021;1–11. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/34233097>
38. Folegatti P, Ewer K, Aley P, Angus B, Becker S B-R, S et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*. 2020;396:467:78.
39. Zhu F, Guan X, Li Y, Huang J, Jiang T, Hou L et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*. 2020;88:396:479.
40. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M E. Concurrent human antibody and TH1 type T-cell responses elicited by a

- Covid-19 RNA vaccine. medRxiv. 2020;
41. Baratawidjaja, Karmen G RI. Imunologi Dasar. Edisi 12. Jakarta: Badan Penerbit FK UI; 2018.
42. Lidiana E, Mustikasari H, Pradana K PA. Gambaran karakteristik kejadian ikutan pasca vaksinasi Covid-19 pada tenaga kesehatan alumni Universitas Aisyiah Surakarta. J Ilm Kesehat [Internet]. 2021;11. Available from: <https://ojs.unsiq.ac.id/index.php/jik/article/view/1817>
43. Li X, Geng M, Peng Y, Meng L LS. Molecular Immune Pathogenesis and Pathogenesis and Diagnosis of Covid-19. J Pharm Anaysis [Internet]. 2020;10(2):102–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/32282863/>
44. Felsenstein S, Herbert J, McNamara P HC. Immunology and Treatment Options. J Clin Immunol [Internet]. 2020;215:108448. Available from: <https://pubmed.ncbi.nlm.nih.gov/32353634/>
45. World Health Organization. Dasar-Dasar Keamanan Vaksin (Pelatihan Melalui Elektronik) [Internet]. 2021. Available from: <https://in.vaccine-safety-training.org>
46. Chen Y, Zuiani A, Fischinger S, Lauffenburger D et al. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. Cell [Internet]. 2020;183(6):1496-1507.e16. Available from: <https://doi.org/10.1016/j.cell.2020.10.051>
47. Pederson. Effect of Exercise on Immune System in Elderly Population. Immunology and Cell Biology. 2007;7:523–31.

48. Muller L, Andre M, Moskorz W, Drezler I, Walotka L, Grothmann R et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 Covid-19 vaccination. *Clin Infect Dis* [Internet]. 2021;73(11):2065–72. Available from: <https://pubmed.ncbi.nlm.nih.gov/33906236/>
49. Salvagno G, Henry B, di Piazza G, Pighi L, De Nitto S, Bragantini D et al. Anti SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing Covid-19 mRNA BNT162b2 Vaccination. *Diagnostics* [Internet]. 2021;11(5):832. Available from: <https://pubmed.ncbi.nlm.nih.gov/34064509/>
50. Sakiani S, Olsen N JKW. Gonadal steroids and humoral immunity. *Nat Rev Endocrinol.* *Nat Rev Endocrinol* [Internet]. 2013;9(1):56–62. Available from: <https://pubmed.ncbi.nlm.nih.gov/23183675/>
51. Klein S FK. Sex differences in immune responses. *Nat Rev Immunol* [Internet]. 2016;16(10):626–638. Available from: <https://www.nature.com/articles/nri.2016.90>
52. Flanagan K, Fink A, Plebanski M KS. Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. *Annu Rev Cell Dev Bi* [Internet]. 2017;33:577–99. Available from: <https://pubmed.ncbi.nlm.nih.gov/28992436/>
53. Bunders M AM. Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. *Immunity* [Internet]. 2020;53(3):487–95. Available from: <https://pubmed.ncbi.nlm.nih.gov/32853545/>

54. Takahashi T, Ellingson M, Wong P, Israelow B, Lucas C, Klein J et al. Sex differences in immune responses that underlie Covid-19 disease outcomes. *Nature* [Internet]. 2020;588(7837):315–320. Available from: <https://www.nature.com/articles/s41586-020-2700-3>
55. Schlickeiser S, Schwarz T, Steiner S, Wittke K, Al Besher N, Meyer O, et al. Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. *Front Immunol* [Internet]. 2021;11:628971. Available from: <https://pubmed.ncbi.nlm.nih.gov/33584731/>
56. Kutsuna S, Asai Y, Matsunaga A, Kinoshita N, Terada M, Miyazato Y, et al. Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from Covid-19. *J Infect Chemother* [Internet]. 2021;27(6):808–13. Available from: <https://pubmed.ncbi.nlm.nih.gov/33531292/>
57. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J et al. A comparison study of SARS-CoV-2 IgG antibody between male and female Covid-19 patients: a possible reason underlying different outcome between sex. *J Med Virol* [Internet]. 2020;92(10):2050–4. Available from: <https://pubmed.ncbi.nlm.nih.gov/32383183/>
58. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* [Internet]. 2020;584(437):42. Available from: <https://doi.org/10.1038/s41586-020-2456-9>

59. Terpos E, Trougakos, I, Apostolakou F, Charitaki I, Sklirou A, Mavrianou N et al. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. *Am J Hematol* [Internet]. 2021;96(7):E257–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/33837984/>
60. Pellini R, Venuti A, Pimpinelli F, Abril E, Blandino G, Campo F, et al. Obesity may hamper SARS-CoV-2 vaccine immunogenicity. *medRxiv* [Internet]. 2021;1–10. Available from: <https://www.medrxiv.org/content/10.1101/2021.02.24.21251664v1>
61. Ibarrondo F, Fulcher J, Goodman-Meza D, Elliott J, Hofmann C H, M et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. *N Engl J Med* [Internet]. 2020;383(11):1085–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/32706954/>
62. Gallais F, Velay A, Nazon C WM-J, Partisani M, Sibilia J et al. Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion. *Emerg Infect Dis J* [Internet]. 2021;27(1):113–21. Available from: <https://pubmed.ncbi.nlm.nih.gov/33261718/>
63. Vandamme B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL et a. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. *Nat Med* [Internet]. 2011;17:179–188. Available from: <https://www.nature.com/articles/nm.2279>
64. Hagan T, Cortese M, Rouphael N, Boudreau C, Linde C, Maddur MS et al. Antibiotics\_Driven Gut Microbiome Perturbation Alters Immunity to

- Vaccines in Human. Cell [Internet]. 2019;178(6):1313-1328. Available from: <https://pubmed.ncbi.nlm.nih.gov/31491384/>
65. Frasca D, Blomberg BB. The Impact of Obesity and Metabolic Syndrome on Vaccination Success. Interdiscip Top Gerontol Geriatr [Internet]. 2020;43:86–97. Available from: <https://miami.pure.elsevier.com/en/publications/the-impact-of-obesity-and-metabolic-syndrome-on-vaccination-succe>
66. WHO Western Pacific Region. The Asia Pacific Perspective: Redefining Obesity and Its Treatment. 2000.
67. Rahayu L, Admiyanti J, Khalda Y, Rudia Ahda F, Agiastany N, Setiawati S, et al. Hipertensi, diabetes melitus, dan obesitas sebagai faktor komorbiditas utama terhadap mortalitas pasien Covid-19: sebuah studi literatur. JIMKI. 2021;9.
68. Kq Yu K, Fischinger S, Smith M, Atyeo M, Cizmeci D, Wolf C, et al. Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2. JCI Insight [Internet]. 2021;6(6):1–18. Available from: <https://pubmed.ncbi.nlm.nih.gov/33621211/>
69. Jain A, Jain A, and Purohit S. Covid-19 , diabetes mellitus , corticosteroids : a recipe for disaster. Ear, Nose& Throat J [Internet]. 2021;1(2):2–3. Available from: <https://pubmed.ncbi.nlm.nih.gov/34281417/>
70. Satoshi Kutsuna, Yusuke Asai, Akihiro Matsunaga, Noriko Kinoshita, Mari Terada, Yusuke Miyazato et al. Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19. J Infect

- Chemother. 2021;7:808–13.
71. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with Covid-19 in Wuhan, China: a retrospective cohort study. Lancet [Internet]. 2020;395(10229):1054–62. Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30566-3/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext)
72. Carlson LE, Speca M, Patel KD G, E. Mindfulnessbased stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology [Internet]. 2004;29(4):448–74. Available from: <https://pubmed.ncbi.nlm.nih.gov/14749092/>
73. Sholeh M. Terapi Sholat Tahajud Menyembuhkan Berbagai Penyakit. Hikmah (PT Mizan Publika). 2006. 147–156 p.
74. Bhat R, Sameer MK GB. Eustress in education: Analysis of the perceived stress score (PSS) and blood pressure (BP) during examinations in Medical Students. J Clin Diagnostic Res [Internet]. 2012;5(7):1331–5. Available from: <https://www.semanticscholar.org/paper/Eustress-in-Education%3A-Analysis-of-the-Perceived-in-Bhat-Mk/35d2f698328201b56517766c86061c7fc6425376>
75. Nasrani L dan PS. Perbedaan tingkat stres antara laki-laki dan perempuan pada peserta yoga di kota Denpasar. E-Jurnal Med Udayana [Internet].

- 2015;4(12). Available from:  
<https://ojs.unud.ac.id/index.php/eum/article/view/18109>
76. Mustika Suci I. Analisis hubungan faktor individu dan beban kerja mental dengan stres kerja. *Indones J Occup Saf Heal* [Internet]. 2018;7(2):220. Available from: <https://e-journal.unair.ac.id/IJOSH/article/view/5256>
77. Rachmat A.S. Faktor-faktor yang mempengaruhi tingkat stress pada tenaga kesehatan di RSUD Daya Makassar selama pandemi Covid-19. [Makasar]: Fakultas Kedokteran dan Ilmu Kesehatan Universitas Muhamadiyah Makasar; 2021.
78. Mindray. Mindray Perbandingan hasil SARS-CoV-2 S RBD IgG Mindray dengan VNT (PRNT 50) dan SVNT Genscript. 2021.
79. Hidayat A. Menghitung Besar Sampel Penelitian [Internet]. 13 Agustus 2020. 2020 [cited 2021 Jul 16]. Available from: <https://www.statistikian.com/2012/08/menghitung-besar-sampel-penelitian.html>
80. Dahlan MS. Statistik Untuk Kedokteran Dan Kesehatan. Edisi 6. Jakarta: Epidemiologi Indonesia; 2010.
81. Zhang H, Liu Y, Liu D, Zeng Q, Li L, Zhou Q et al. Time of day influences immune response to an inactivated vaccine against SARS-CoV-2. *Cell Res* [Internet]. 2021;31(11):1215–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/34341489/>
82. World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac

- [Internet]. 2021 [cited 2021 Oct 30]. p. 1–8. Available from: [https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE\\_recommendation-Sinovac-CoronaVac-2021.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-2021.1)
83. Susilo A, Rumende C, Pitoyo C, Santoso W, Yulianti M, Herikurniawan et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. J Penyakit Dalam. 2020;7(1):45.
84. Darmojo. Keperawatan Gerontik. Jakarta: EGC; 2010.
85. Fatmah. Gizi Usia Lanjut. Jakarta: Erlangga; 2010.
86. Iqbal M. Hubungan Indeks Massa Tubuh ( IMT ) dan ukuran lingkar perut Terhadap kadar antibodi SARS-CoV-2 [Internet]. Universitas Sriwijaya; 2021. Available from: [https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjxh-aosf71AhU7UWwGHdoxC2UQFnoECBEQAQ&url=https%3A%2F%2Frepository.unsri.ac.id%2F61310%2F3%2FRAMA\\_11201\\_04011281823108\\_0029127201\\_0003088102\\_01\\_front\\_ref.pdf&usg=AOvVaw04rmzalF7dOgfA](https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjxh-aosf71AhU7UWwGHdoxC2UQFnoECBEQAQ&url=https%3A%2F%2Frepository.unsri.ac.id%2F61310%2F3%2FRAMA_11201_04011281823108_0029127201_0003088102_01_front_ref.pdf&usg=AOvVaw04rmzalF7dOgfA)